Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia

British Journal of Haematology

Volumn 142, Issue 2, 2008, Pages 284-292

  Holowiecki, Jerzy ^a   Giebel, Sebastian ^a   Wojnar, Jerzy ^a   Krawczyk Kulis, Malgorzata ^a   Markiewicz, Miroslaw ^a   Holowiecka Goral, Aleksandra ^a   Freund, Mathias ^b   Casper, Jochen ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

CML; HSC transplantation; Treosulfan

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; MEDAC; METHOTREXATE; THYMOCYTE ANTIBODY; TREOSULFAN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; CHIMERA; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; INFECTION; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 47249124510     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07179.x     Document Type: Article

References (29)

1. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R. Hehlmann, R. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, 1809 1820.
2. Bornhauser, M., Kroger, N., Schwerdtfeger, R., Schafer-Eckart, K., Sayer, H.G., Scheid, C., Stelljes, M., Kienast, J., Mundhenk, P., Fruehauf, S., Kiehl, M. G., Wandt, H., Theuser, C., Ehninger, G. Zander, A.R. (2006) Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. European Journal of Haematology, 76, 9 17.
3. Carreras, E., Jimenez, M., Gomez-Garcia, V., de la Camera, R., Martin, C., Martinez, F., Iriondo, A., Sanz, G., Canizo, C., Cabrera, R., Sierra, J., Vallejo, C., Lopez, J., Martinez, C., Rovira, M., Fernandez-Ranada, J.M. Torres, A. (2006) Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplantation, 37, 33 40.
4. Casper, J., Knauf, W., Kiefer, T., Wolff, D., Steiner, B., Hammer, U., Wegener, R., Kleine, H.D., Wilhelm, S., Knopp, A., Hartung, G., Dolken, G. Freund, M. (2004a) Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood, 103, 725 731.
5. Casper, J., Knauf, W., Blau, I., Ruutu, T., Volin, L., Wandt, H., Schafer-Eckart, K., Holowiecki, J., Giebel, S., Aschan, J., Zander, A., Kroger, N., Doelken, G. Freund, M. (2004b) Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Annals of Hematology, 83, S70 S71.
6. Crawley, C., Szydlo, R., Lalancette, M., Bacigalupo, A., Lange, A., Brune, M., Juliusson, G., Nagler, A., Gratwohl, A., Passweg, J., Komarnicki, M., Vitek, A., Mayer, J., Zander, A., Sierra, J., Rambaldi, A., Ringden, O., Niederwieser, D. Apperley, J.F. (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood, 106, 2969 2976.
7. Deininger, M., Schleuning, M., Greinix, H., Sayer, H. G., Fischer, T., Martinez, J., Maziarz, R., Olavarria, E., Verdonck, L., Schaefer, K., Boque, C., Faber, E., Nagler, A., Pogliani, E., Russell, N., Volin, L., Schanz, U., Doelken, G., Kiehl, M., Fauser, A., Druker, B., Sureda, A., Iacobelli, S., Brand, R., Krahl, R., Lange, T., Hochhaus, A., Gratwohl, A., Kolb, H. Niederwieser, D. (2006) The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 91, 452 459.
8. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408 2417.
9. Giralt, S.A., Arora, M., Goldman, J.M., Lee, S.J., Maziarz, R.T., McCarthy, P.L., Sobocinski, K.A. Horowitz, M.M., Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research 2007) Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. British Journal of Haematology, 137, 461 467.
10. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K. G. Thomas, E.D. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 18, 295 304.
11. Gooley, T.A., Leisenring, W., Crowley, J. Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695 706.
12. Gratwohl, A., Hermans, J., Goldman, J.M., Arcese, W., Carreras, E., Devergie, A., Frassoni, F., Gahrton, G., Kolb, H.J., Niederwieser, D., Ruutu, T., Vernant, J.P., de Witte, T. Apperley, J. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood and marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet, 352, 1087 1092.
13. Gratwohl, A., Brand, R., Apperley, J., Crawley, C., Ruutu, T., Corradini, P., Carreras, E., Devergie, A., Guglielmi, C., Kolb, H.J. Niederwieser, D. (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 91, 513 521.
14. Guglielmi, C., Arcese, W., Dazzi, F., Brand, R., Bunjes, D., Verdonck, L.F., Schattenberg, A., Kolb, H.J., Ljungman, P., Devergie, A., Bacigalupo, A., Gomez, M., Michallet, M., Elmaagacli, A., Gratwohl, A., Apperley, J. Niederwieser, D. (2002) Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood, 100, 397 405.
15. Hehlmann, R., Berger, U., Pfirrmann, M., Heimpel, H., Hochhaus, A., Hasford, J., Kolb, H. J., Lahaye, T., Maywald, O., Reiter, A., Hossfeld, D.K., Huber, C., Loffler, H., Pralle, H., Queisser, W., Tobler, A., Nerl, C., Solenthaler, M., Goebeler, M.E., Griesshammer, M., Fischer, T., Kremers, S., Eimermacher, H., Pfreundschuh, M., Hirschmann, W.D., Lechner, K., Wassmann, B., Falge, C., Kirchner, H.H. Gratwohl, A. (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 109, 4686 4692.
16. Kaplan, E.L. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
17. Oehler, V.G., Gooley, T., Snyder, D.S., Johnston, L., Lin, A., Cummings, C.C., Chu, S., Bhatia, R., Forman, S.J., Negrin, R.S., Appelbaum, F.R. Radich, J.P. (2007) The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood, 109, 1782 1789.
18. Olavarria, E., Siddique, S., Griffiths, M.J., Avery, S., Byrne, J.L., Piper, K.P., Lennard, A.L., Pallan, L., Arrazi, J.M., Perz, J.B., O'Shea, D., Goldman, J.M., Apperley, J.F. Craddock, C.F. (2007) Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood, 110, 4614 4617.
19. van Pel, M., van Breugel, D.W., Vos, W., Ploemacher, R.E. Boog, C.J. (2003) Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplantation, 32, 15 22.
20. Ploemacher, R.E., Johnson, K.W., Rombouts, E.J., Etienne, K., Westerhof, G.R., Baumgart, J., White-Scharf, M.E. Down, J.D. (2004) Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biology of Blood and Marrow Transplantation, 10, 236 245.
21. Radich, J.P., Gooley, T., Bensinger, W., Chauncey, T., Clift, R., Flowers, M., Martin, P., Slattery, J., Sultan, D. Appelbaum, F.R. (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood, 102, 31 35.
22. Ringhoffer, M., Harsdorf, S., Schmitt, M., Wiesneth, M., Zenz, T., Stilgenbauer, S., Greiner, J., Döhner, K., Marx, M., Döhner, H. Bunjes, D. (2007) Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. British Journal of Haematology, 136, 127 130.
23. Shimoni, A., Kroger, N., Zander, A.R., Rowe, J.M., Hardan, I., Avigdor, A., Yeshurun, M., Ben-Bassat, I. Nagler, A. (2003) Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 17, 290 297.
24. Silver, R.T., Woolf, S.H., Hehlmann, R., Appelbaum, F.R., Anderson, J., Bennett, C., Goldman, J.M., Guilhot, F., Kantarjian, H.M., Lichtin, A.E., Talpaz, M. Tura, S. (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 94, 1517 1536.
25. Simula, M.P., Marktel, S., Fozza, C., Kaeda, J., Szydlo, R.M., Nadal, E., Bua, M., Rahemtulla, A., Kanfer, E., Marin, D., Olavarria, E., Goldman, J.M., Apperley, J.F. Dazzi, F. (2007) Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia, 21, 943 948.
26. Socié, G., Clift, R.A., Blaise, D., Devergie, A., Ringden, O., Martin, P.J., Remberger, M., Deeg, H.J., Ruutu, T., Michallet, M., Sullivan, K.M. Chevret, S. (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood, 98, 3569 3574.
27. Storb, R., Prentice, R.L., Sullivan, K.M., Shulman, H.M., Deeg, H.J., Doney, K.C., Buckner, C.D., Clift, R.A., Witherspoon, R.P., Appelbaum, F.A., Sanders, J.E., Stewart, P.S. Thomas, E.D. (1983) Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Annals of Internal Medicine, 98, 461 466.
28. Weisser, M., Ledderose, G. Kolb, H.J. (2007) Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. Annals of Hematology, 86, 127 132.
29. Zaucha, J.M., Prejzner, W., Giebel, S., Gooley, T.A., Szatkowski, D., Kalwak, K., Wojnar, J., Kruzel, T., Balon, J., Holowiecki, J. Hellmann, A. (2005) Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplantation, 36, 417 424.